Andronova V L, Galegov G A, Musiyak V V, Vozdvizhenskaya O A, Levit G L, Krasnov V P
FSBI «National Research Center of Epidemiology and Microbiology named after honorary academician N.F. Gamaleya» of the Ministry of Health of Russia.
FSBIS I.Ya. Postovsky Institute of Organic Synthesis of the Ural Branch of the Russian Academy of Sciences.
Vopr Virusol. 2021 Jan 7;65(6):373-380. doi: 10.36233/0507-4088-2020-65-6-8.
Herpes simplex viruses type 1 (HSV-1) are extremely widespread throughout the world and, similar to other herpesviruses, establish lifelong persistent infection in the host. Reactivating sporadically, HSV-1 elicits recurrences in both immunocompetent and immunocompromised individuals and can cause serious diseases (blindness, encephalitis, generalized infections). The currently available antiherpetic drugs that aimed mainly at suppressing replication of viral DNA are not always effective enough, for example, due to the development of drug resistance. As we showed earlier the newly discovered compound LAS-131 exhibits the strong and highly selective inhibitory activity against HSV‑1, including strain resistant to acyclovir (selective index, SI = 63). The presence of LAS-131 at a concentration of 20 μg/ml leads to a decrease in the titer of HSV-1 (strain L2) by 4 lg in a one round of HSV-1 replication.
To establish the step(s) of the virus life cycle that is sensitive to the action of LAS-131, we have applied a widely used approach, that made it possible to determine how long the addition of a compound can be postponed before it loses its antiviral activity (time-of-addition assay), and to compare this indicator with the crucial time of application of inhibitors with a well-known mechanism of action (in cell culture).
It has been shown for the first time that LAS-131 retains a pronounced antiviral effect when introduced into the experimental system no later than 9 hours post-infection (p.i.). However, LAS-131 does not affect the release of HSV-1 from the cell.
Together with published data on the termination of the synthesis of viral DNA 9-12 h after the adsorption in a cell culture infected with HSV with a high multiplicity (≥1 PFU/cell), our results suggest that LAS-131 interferes the life cycle of HSV-1 during synthesis of viral DNA. Further studies of the mechanism of action are necessary to establish definitely the biological target for this compound,.
1型单纯疱疹病毒(HSV-1)在全球广泛传播,与其他疱疹病毒一样,能在宿主体内建立终身持续性感染。HSV-1偶尔复发,在免疫功能正常和免疫功能低下的个体中都会引发复发,并可导致严重疾病(失明、脑炎、全身性感染)。目前可用的主要旨在抑制病毒DNA复制的抗疱疹药物并不总是足够有效,例如,由于耐药性的产生。正如我们之前所表明的,新发现的化合物LAS-131对HSV-1表现出强烈且高度选择性的抑制活性,包括对阿昔洛韦耐药的毒株(选择性指数,SI = 63)。在一轮HSV-1复制中,浓度为20μg/ml的LAS-131可使HSV-1(L2毒株)的滴度降低4个对数。
为了确定病毒生命周期中对LAS-131作用敏感的步骤,我们采用了一种广泛使用的方法,该方法能够确定在化合物失去其抗病毒活性之前可以推迟添加多长时间(添加时间试验),并将该指标与具有已知作用机制的抑制剂在细胞培养中的关键应用时间进行比较。
首次表明,在感染后(p.i.)不迟于9小时引入实验系统时,LAS-131仍具有显著的抗病毒作用。然而,LAS-131不影响HSV-1从细胞中释放。
连同已发表的关于在高感染复数(≥1 PFU/细胞)感染HSV的细胞培养物中吸附后9 - 12小时病毒DNA合成终止的数据,我们的结果表明LAS-131在病毒DNA合成期间干扰HSV-1的生命周期。需要进一步研究作用机制以明确该化合物的生物学靶点。